TL;DR
Prime made for students and young adults
- Fast, free delivery for dorm and study essentials
- Prime Video and Amazon Music included
- Member-only deals
NIH and NASA announced the QuSAFE Challenge, offering up to $7.1 million in prizes for quantum-enabled sensing approaches for in-vitro models used in toxicity and safety research. Submissions are scheduled to open Dec. 15, 2026, and close July 27, 2027; details on winners and award distribution were not included in NASA’s announcement.
NASA and the National Institutes of Health have announced the QuSAFE Challenge, a prize competition seeking quantum-enabled sensing methods for in-vitro models used to study toxicity and drug safety. The challenge offers up to $7.1 million in prizes, with submissions scheduled to open Dec. 15, 2026, and close July 27, 2027, according to NASA.
QuSAFE stands for Quantum-Enabled Predictive Preclinical NAMs for Toxicity and Safety. NASA says the competition aims to advance sensing for in-vitro new approach methodologies, or NAMs, including organoids and microphysiological systems. These models can produce human-relevant data for drug development and safety evaluation without relying solely on animal studies.
NASA’s announcement says conventional assays and imaging can be noisy, invasive, or insufficiently sensitive to detect weak, early, or low-abundance biological signals. It also says destructive measurements can make it difficult to follow biological processes over time. The challenge is intended to encourage sensors that can address those measurement limitations; the announcement does not identify a selected technology or a winning team.
NASA describes quantum-enabled sensing as offering potential for high sensitivity, stronger signal-to-noise performance, and nanoscale resolution. Those are the capabilities the agency says could help detect signals that current methods may miss. The announcement frames them as potential advantages of the approach, not as demonstrated outcomes from QuSAFE-funded work.
Improving Signals in Drug Safety Models
The challenge targets a practical problem in preclinical research: if a model produces useful human-relevant information but available tools cannot reliably measure its changing signals, researchers may have difficulty interpreting its response to a drug or potential toxic effect. More sensitive, less disruptive monitoring could help investigators observe biological processes across time rather than relying on a single endpoint or a measurement that damages the sample.
For readers, the main point is that QuSAFE is a research and technology competition, not a report that a new test is ready for clinical or regulatory use. If entrants develop tools that perform as intended, the work could support more informative in-vitro studies and contribute to efforts to reduce animal use. NASA also links the effort to space research, where the agency says advanced detection methods are needed beyond traditional laboratory settings. The announcement does not quantify expected reductions in animal testing or state how quickly any resulting technology could be adopted.
The award ceiling makes the competition a substantial public-sector investment in sensing research, but up to $7.1 million does not establish that the full amount will be awarded. NASA’s notice does not provide a breakdown of prize amounts, the number of awards, or the evaluation criteria.
Popular right now
Breville Bambino Espresso Machine, Brushed Stainless Steel (BES450BSS)
Dyson Car+Boat Cordless Handheld Vacuum
KitchenAid Classic Series 4.5-Quart Tilt-Head Stand Mixer, Onyx Black
As an affiliate, we earn on qualifying purchases.
Why NASA and NIH Back QuSAFE
NASA says the challenge supports its Biological and Physical Sciences Division and draws on sensor-development research communities. The agency presents the work as relevant to both space exploration and science on Earth. NIH’s participation connects the competition to preclinical toxicity and safety research, although the announcement gives no further description of the agencies’ respective roles in judging or administering the challenge.
In-vitro NAMs include laboratory models intended to provide alternatives or complements to conventional animal studies. Organoids are small, organized cell models, while microphysiological systems recreate selected features of human tissues or organs. NASA’s stated rationale is that these systems can be useful for drug development, but their value depends in part on the ability to measure biological changes accurately and over time.
NASA published its announcement on Oct. 29, 2026, and directed prospective entrants to the QuSAFE Challenge website for registration, rules, and eligibility information. The agency’s notice establishes the submission schedule and prize ceiling but does not report that applications have opened or that awards have been made.
Prize Rules and Results Still Pending
NASA’s announcement does not state how the up to $7.1 million will be divided, how many prizes may be awarded, or what technical benchmarks entrants must meet. It also does not name participating research teams, describe a judging panel, or specify whether prototypes, demonstrations, or other deliverables will be required.
The announcement describes possible advantages of quantum-enabled sensing, but it provides no QuSAFE test results or evidence that a particular sensor has already solved the measurement challenges outlined. It remains unclear how the competition will assess performance in organoids or microphysiological systems, and how any successful approach would be validated for drug-safety research. NASA’s notice also does not give a timetable for judging or announcing winners.
Any future reduction in animal use, improvement in drug-safety decisions, or application in space research is not quantified in the announcement. Those outcomes depend on the technologies submitted, their performance, and later research or validation.
Submission Window Opens in December
NASA lists Dec. 15, 2026, as the opening date for submissions and July 27, 2027, as the closing date. Prospective entrants are directed to the QuSAFE Challenge website for registration, rules, and eligibility details. The announcement does not give an award decision date.
The next concrete information for teams will be the competition’s full entry requirements and evaluation process. After submissions open, details about eligible participants, required technical evidence, and how judges will compare proposals will determine what solutions the challenge can attract. NASA or NIH may provide further information as the competition proceeds; no winner or funded project has been identified in the announcement.
Key Questions
What is the NIH-NASA QuSAFE Challenge?
It is a prize competition seeking quantum-enabled sensing approaches for in-vitro new approach methodologies, including organoids and microphysiological systems, used in toxicity and drug-safety research.
How much prize money is available?
NASA lists up to $7.1 million in prizes. The announcement does not explain how many awards may be made or how the total will be divided.
When can teams submit entries?
NASA says submissions open on Dec. 15, 2026, and close on July 27, 2027. Registration, rules, and eligibility information are available through the challenge website named in NASA’s announcement.
Does QuSAFE mean animal testing will end?
No such outcome is confirmed. NASA says the challenge supports in-vitro models that can generate human-relevant data and describes reducing animal use as part of the effort’s aim. Its announcement does not quantify any reduction or say that animal studies will be eliminated.
Have any winning technologies been announced?
No. NASA’s Oct. 29 announcement describes the competition and its schedule; it does not name entrants, report results, or identify winning technologies.
Source: nasa.gov
